In cancer, Gal-3 is frequently overexpressed and contributestomultiple hallmarks of malignancy. Itfosters immune evasion by inhibiting T cell activation and promotingregulatory T cell function, while also enhancing metastasis throughtumor–endothelium adhesion and extracellular matrix interactions.Elevated Gal-3 expression has been associated with poor prognosisin several cancers, including nonsmall-cell lung cancer, melanoma,and colorectal carcinoma., These compartment-specificand context-dependent roles make Gal-3 an attractive, yet mechanisticallycomplex, therapeutic target. This evidence concerns the gene LGALS3 and colorectal carcinoma.